Eltrombopag for Post-Transplant Poor Graft Function in East Asian Patients

Overview

Journal J Korean Med Sci

Specialty General Medicine

Date 2022 Feb 15

PMID 35166084

Authors

Hyun Jin Ahn

Ja Min Byun

InHo Kim

Jeonghwan Youk

Youngil Koh

Dong-Yeop Shin

Junshik Hong

Sung-Soo Yoon

Affiliations

Soon will be listed here.

Abstract

Poor graft function (PGF) is a serious, potentially life-threatening complication of allogeneic hematopoietic stem cell transplantation. Eltrombopag has shown multilineage responses in patients with refractory severe aplastic anemia, supporting the idea that it may improve cytopenia in patients with PGF. This retrospective, single center analysis included 8 Korean patients receiving eltrombopag for PGF. Median interval between transplant and eltrombopag treatment was 73 days, and the median duration treatment was 3.5 weeks. With median maximum daily dose of 50 mg, the time to best response was 93 days. Median hemoglobin increased from 8.2 g/dL to 10.9 g/dL, platelet from 18.5 × 10/L to 54 × 10/L, and absolute neutrophil count from 1.25 × 10/L to 3.32 × 10/L. In conclusion, eltrombopag is a good option for PGF in Korean patients, even at a lower dose compared to western patients.

Citing Articles

Thrombopoietin Receptor Agonists in Post-Hematopoietic Cell Transplantation Complicated by Prolonged Thrombocytopenia: A Comprehensive Review.

Elsayed A, Elsayed B, Elmarasi M, Elsabagh A, Elsayed E, Elmakaty I Immunotargets Ther. 2024; 13:461-486.

PMID: 39290805 PMC: 11407319. DOI: 10.2147/ITT.S463384.

Successful recovery of poor graft function by administration of romiplostim in a multiple myeloma case with poor graft function following autologous stem cell transplantation.

Yim J, Park S, Lee J, Yoon J, Kim H, Min C Blood Res. 2023; 58(4):237-240.

PMID: 38031472 PMC: 10758637. DOI: 10.5045/br.2023.2023185.

References

Mahat U, Rotz S, Hanna R . Use of Thrombopoietin Receptor Agonists in Prolonged Thrombocytopenia after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019; 26(3):e65-e73. DOI: 10.1016/j.bbmt.2019.12.003. View

Wong R, Saleh M, Khelif A, Salama A, Portella M, Burgess P . Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017; 130(23):2527-2536. DOI: 10.1182/blood-2017-04-748707. View

Lee K, Choi S, Lee J, Kim S, Seol M, Lee Y . Failure of trilineage blood cell reconstitution after initial neutrophil engraftment in patients undergoing allogeneic hematopoietic cell transplantation - frequency and outcomes. Bone Marrow Transplant. 2004; 33(7):729-34. DOI: 10.1038/sj.bmt.1704428. View

ONeill A, Chin D, Tan D, Abdul Majeed A, Nakamura-Ishizu A, Suda T . Thrombopoietin maintains cell numbers of hematopoietic stem and progenitor cells with megakaryopoietic potential. Haematologica. 2020; 106(7):1883-1891. PMC: 8252958. DOI: 10.3324/haematol.2019.241406. View

Olnes M, Scheinberg P, Calvo K, Desmond R, Tang Y, Dumitriu B . Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012; 367(1):11-9. PMC: 3422737. DOI: 10.1056/NEJMoa1200931. View

Kong Y . Poor graft function after allogeneic hematopoietic stem cell transplantation-an old complication with new insights. Semin Hematol. 2019; 56(3):215-220. DOI: 10.1053/j.seminhematol.2018.08.004. View

Gibiansky E, Zhang J, Williams D, Wang Z, Ouellet D . Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. J Clin Pharmacol. 2010; 51(6):842-56. DOI: 10.1177/0091270010375427. View

Marotta S, Marano L, Ricci P, Cacace F, Frieri C, Simeone L . Eltrombopag for post-transplant cytopenias due to poor graft function. Bone Marrow Transplant. 2019; 54(8):1346-1353. DOI: 10.1038/s41409-019-0442-3. View

Stasia A, Ghiso A, Galaverna F, Raiola A, Gualandi F, Luchetti S . CD34 selected cells for the treatment of poor graft function after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2014; 20(9):1440-3. DOI: 10.1016/j.bbmt.2014.05.016. View

10.

Tanaka T, Inamoto Y, Yamashita T, Fuji S, Okinaka K, Kurosawa S . Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016; 22(5):919-24. DOI: 10.1016/j.bbmt.2016.01.018. View

11.

Kim Y, Lee S, Jeong S, Ahn J, Yang D, Lee J . Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia. Blood Res. 2015; 50(1):19-25. PMC: 4377333. DOI: 10.5045/br.2015.50.1.19. View

12.

Erickson-Miller C, Delorme E, Tian S, Hopson C, Landis A, Valoret E . Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2008; 27(2):424-30. PMC: 2729672. DOI: 10.1634/stemcells.2008-0366. View

13.

Liu X, Wu M, Peng Y, Chen X, Sun J, Huang F . Improvement in poor graft function after allogeneic hematopoietic stem cell transplantation upon administration of mesenchymal stem cells from third-party donors: a pilot prospective study. Cell Transplant. 2013; 23(9):1087-98. DOI: 10.3727/096368912X661319. View

14.

Bento L, Bastida J, Garcia-Cadenas I, Garcia-Torres E, Rivera D, Bosch-Vilaseca A . Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant. Biol Blood Marrow Transplant. 2019; 25(9):1825-1831. DOI: 10.1016/j.bbmt.2019.05.023. View

15.

Halahleh K, Gale R, Dana W, Makoseh M, Saadeh S, Alan W . Therapy of posttransplant poor graft function with eltrombopag. Bone Marrow Transplant. 2020; 56(1):4-6. DOI: 10.1038/s41409-020-0975-5. View

16.

Tang C, Chen F, Kong D, Ma Q, Dai H, Yin J . Successful treatment of secondary poor graft function post allogeneic hematopoietic stem cell transplantation with eltrombopag. J Hematol Oncol. 2018; 11(1):103. PMC: 6097332. DOI: 10.1186/s13045-018-0649-6. View

17.

Rivera D, Bastida J, Lopez-Corral L, Sanchez-Guijo F, Cabrero M, Martin A . Usefulness of eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation. Bone Marrow Transplant. 2018; 54(5):757-761. DOI: 10.1038/s41409-018-0368-1. View